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Recombinant human growth hormone (GH) has been
used as an effective treatment for short stature since the
late 1980’s. Although clinical trials were crucial in devel-
oping GH treatment strategies, database analyses have
the potential to provide additional information with
regard to treatment efficacy and safety. The OZGROW
database was established in 1989 as an initiative of the
Australasian Paediatric Endocrine Group (APEG) to
allow monitoring of children receiving GH under the
national Pharmaceutical Benefits Scheme (PBS). There
are currently (June 2014) 1948 children receiving subsi-
dised GH treatment in Australia and the OZGROW
database contains records from 6959 individuals. This
unique resource has allowed a number of clinically rele-
vant questions to be addressed.
Defining short stature and therefore eligibility for GH
treatment relies on the use of appropriate growth stan-
dards. There has been debate as to whether the World
Health Organisation (WHO) or the Center for Disease
Control (CDC) growth charts best describe the heights of
contemporary Australian children. There appears to have
been a positive secular trend for height in Australian chil-
dren such that both charts under-estimate the number of
children eligible for growth hormone treatment.
Ascertainment bias has been proposed as an explana-
tion for the fact that more boys than girls receive GH
treatment. Analysis of the OZGROW database demon-
strated that ascertainment bias did not appear to be a
major factor explaining the gender discrepancy. It is pos-
sible that biological factors influencing the tempo of
growth and development may contribute to the greater
number of boys receiving growth hormone.
Another issue that has complicated comparisons of
international studies of growth hormone response has
been the different dosing schedules used. A simple
method for converting weight and surface area based
doses was therefore developed. Further analysis sug-
gested that the surface area based protocol used in
Australia may disadvantage older children, given that
the dose per kilogram reduces over time even if the
dose per meter squared remains constant.
The importance of commencing GH treatment early
and maximising height gain during the first year of
treatment was also highlighted by analysing GH respon-
siveness in a number of conditions including Turner
syndrome, Prader-Willi syndrome and idiopathic short
stature. Ensuring that referring physicians are able to
diagnose these conditions in a timely fashion therefore
remains a priority.
Although the OZGROW database has allowed clini-
cally relevant questions to be studied there remain a
number of challenges, particularly with regard to long
term follow up.
Acknowledgements
Presented on behalf of OZGROW subcommittee members
Authors’ details
1OZGROW & Mater Research, UQ Institute, Brisbane, QLD, Australia. 2Mater
Children’s Hospital, Brisbane, QLD, Australia. 3Princess Margaret Hospital
Perth, Perth, WA, Australia. 4School of Pediatrics and Child Health, University
of Western Australia, Perth, WA, Australia. 5Liggins Institute, Auckland, New
Zealand. 6University of Auckland, Auckland, New Zealand. 7The Royal
Children’s Hospital, Melbourne, VIC, Australia. 8Murdoch Children’s Research
Institute, Melbourne, VIC, Australia. 9Institute of Endocrinology and Diabetes,
The Children’s Hospital at Westmead, Sydney, NSW, Australia. 10School of
Women’s and Children’s Health,, The University of Sydney Medicine, Sydney,
NSW, Australia. 11Institute of Endocrinology and Diabetes, The Children’s
Hospital Westmead, Sydney, NSW, Australia. 12Discipline of Paediatrics and
Child Health, University of Sydney, Sydney, NSW, Australia. 13Lady Cilento
Children’s Hospital, Brisbane, QLD, Australia.1OZGROW & Mater Research, UQ Institute, Brisbane, QLD, Australia
Full list of author information is available at the end of the article
Hughes et al. International Journal of Pediatric Endocrinology 2015, 2015(Suppl 1):O4
http://www.ijpeonline.com/content/2015/S1/O4
© 2015 Hughes et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 28 April 2015
doi:10.1186/1687-9856-2015-S1-O4
Cite this article as: Hughes et al.: How databases inform clinical
management – insights from ozgrow. International Journal of Pediatric
Endocrinology 2015 2015(Suppl 1):O4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Hughes et al. International Journal of Pediatric Endocrinology 2015, 2015(Suppl 1):O4
http://www.ijpeonline.com/content/2015/S1/O4
Page 2 of 2
